Tags:ActiveChemicalDevelopmentManufacturingMedtechPhysicalProductSpecialtyTechnology
Focused on the commercialization and development of abuse-resistant opioid formulations.
Member count: 11-50
Total raised: $34.3M
Founded date: 1995

Investors 2

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
16.09.2013-$20M-finsmes.co...
07.05.2012Series B$14.3M-finsmes.co...

Mentions in press and media 7

DateTitleDescriptionCategoryAuthorSource
11.07.2017Egalet Clo...Egalet Corporation (Nasdaq: EG...--citybizlis...
16.09.2013Egalet Clo...Egalet Ltd., a London, UK- and...funding S...-finsmes.co...
13.09.2013Egalet sco...Egalet has found more venture ...Venture Ca...-fiercebiot...
08.05.2012Abuse-resi...Egalet’s erosion technology me...--medcitynew...
07.05.2012Egalet Ann... MALVERN, PA, Privately held ...--vcnewsdail...
07.05.2012Egalet Rai...Egalet Ltd., a Værløse , Denma...Denmark f...-finsmes.co...
-Abuse-resi...A drugmaker specializing in ex...--medcitynew...